Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.64 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 2.2× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Vanguard Emerging Markets Stock Index Fund ETF for 134 Days on average.
| REGN | VWO | |
|---|---|---|
Market Cap | $76.14B | $168.50B |
Volume | 500,239 | 9,650,999 |
Sector | Health | — |
52-Week High | $852.03 | $61.44 |
52-Week Low | $557.73 | $52.42 |
Typical Hold Time | 107 Days | 134 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
VWO trades at $59.85, down 1.27% with a bearish technical signal. The ETF faces mixed sentiment as AI-driven Taiwan exposure provides strength while China's economic weakness creates headwinds. Institutional ownership has increased with Allianz Asset Management growing its stake by 12.6% in Q3 2026, though technical indicators show selling pressure outweighing buying signals.
The outlook remains cautious with emerging markets facing economic divergence. Opportunities exist in semiconductor and technology exposure, but risks include China's property slump and currency volatility. Wall Street sentiment is neutral with the ETF trading near key support levels amid global market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
